As a result, HRAS mutant squamous- and head and neck cancers, NRAS mutant novel melanomas or myelomonocytic leukemia and KRAS mutant colorectal cancers could be developed upon BRAF inhibitor therapies (38, 39, 40). This evidence concerns the gene BRAF and melanoma.